Edina Komlodi-Pasztor

Dr. Edina Komlodi-Pasztor


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
JRJames L. Rogers
James L. Rogers
TWThomas Wall
Thomas Wall
AAAlvina A. Acquaye-Mallory
Alvina A. Acquaye-Mallory
LBLisa Boris
Lisa Boris
YKYeonju Kim
Yeonju Kim
MPMarta Penas-Prado
Marta Penas-Prado
Purpose: Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers. Methods: We retrospectively reviewed records from virtual MTBs held between 04/2020–03/2021. Data collected included measures of potential clinical impact, including referrals to observational or therapeutic studies, referrals for specialized neuropathology analysis, and whether molecular findings led to a change in diagnosis and/or guided management suggestions. Results: During 25 meetings, 32 presenters discussed 44 cases. Approximately half (n = 20; 48%) involved a rare central nervous system (CNS) tumor. In 21% (n = 9) the diagnosis was changed or refined based on molecular profiling obtained at the NIH and in 36% (n = 15) molecular findings guided management. Clinical trial suggestions were offered to 31% (n = 13), enrollment in the observational NCI Natural History Study to 21% (n = 9), neuropathology review and molecular testing at the NIH to 17% (n = 7), and all received management suggestions. Conclusion: Virtual multi-institutional MTBs enable remote expert review of CNS tumors. We propose them as a strategy to facilitate expert opinions from specialized centers, especially for rare CNS tumors, helping mitigate geographic barriers to patient care and serving as a pre-screening tool for studies. Advanced molecular testing is key to obtaining a precise diagnosis, discovering potentially actionable targets, and guiding management.

30 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
EKEdina Komlodi-Pasztor
Edina Komlodi-Pasztor
VUVindhya Udhane
Vindhya Udhane
JWJoseph Watson
Joseph Watson
ESEmily A Sloan
Emily A Sloan
ASAnousheh Sayah
Anousheh Sayah
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background and Clinical Significance: Primary central nervous system (CNS) germinomas are rare intracranial germ cell tumors that predominantly affect children and young adults. Histopathological evaluation remains the diagnostic gold standard; however, molecular characterization has increasingly contributed to tumor classification and biological understanding. Recent advances in cerebrospinal fluid tumor-derived nucleic acid (CSF-tNA) analysis provide an opportunity to identify tumor-associated genomic alterations through minimally invasive testing; however, its ability to distinguish CNS germ cell tumor subtypes has not been established and it should be interpreted as a complementary rather than standalone diagnostic tool. Case Presentation: We report a patient with an intracranial mass whose histopathological examination demonstrated features consistent with germinoma. Immunohistochemistry confirmed the diagnosis. Concurrent CSF-tNA analysis using Summit™ 2.0 assay revealed a 12p gain encompassing KRAS, along with copy number gains of chromosome arms 21q and 1q and losses of chromosome arms 11q, 13q, 5q, and 9q. Although these alterations overlap with molecular profiles reported in CNS germ cell tumors, including recurrent 12p gain and RAS/MAPK pathway activation, they cannot distinguish germinoma from other CNS germ cell tumor subtypes and should be interpreted in conjunction with histopathologic, radiographic, and clinical findings. Conclusions: This case illustrates the potential complementary role of CSF genomic profiling alongside conventional histopathology. CSF-based genomic analysis may contribute to supportive molecular information and may have future applications in disease monitoring rather than definitive tumor classification or subtype discrimination.